These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 39213140

  • 1. Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes.
    Wang Y, Kang SY, Socal MP, Dusetzina SB.
    J Manag Care Spec Pharm; 2024 Sep; 30(9):903-907. PubMed ID: 39213140
    [Abstract] [Full Text] [Related]

  • 2. On the motivation for pharmaceutical manufacturer coupons: Brand loyalty or customer acquisition?
    Gibbons JB, Hermosilla M, Trujillo A.
    Health Serv Res; 2024 Sep 01. PubMed ID: 39219365
    [Abstract] [Full Text] [Related]

  • 3. The impact of manufacturer coupon use in the statin market.
    Daugherty JB, Maciejewski ML, Farley JF.
    J Manag Care Pharm; 2013 Sep 01; 19(9):765-72. PubMed ID: 24156645
    [Abstract] [Full Text] [Related]

  • 4. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 01; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M, Peng X, Geremakis C, Bae J.
    J Manag Care Spec Pharm; 2015 Dec 01; 21(12):1204-12. PubMed ID: 26679969
    [Abstract] [Full Text] [Related]

  • 6. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D, Lee TA, Schumock GT, Walton SM, Gerber BS, Nutescu EA, Touchette DR.
    J Manag Care Spec Pharm; 2020 Jan 01; 26(1):67-75. PubMed ID: 31880221
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel-Farrant H, Smeeth L, Douglas IJ, Tomlinson LA.
    Diabetes Obes Metab; 2020 May 01; 22(5):847-856. PubMed ID: 31957254
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V, Driessen JHM, Starup-Linde JK, Al-Mashhadi ZK, Viggers R, Klungel OH, Souverein PC, Vestergaard P, Stehouwer CDA, van den Bergh JP.
    Diabetes Obes Metab; 2023 Nov 01; 25(11):3235-3247. PubMed ID: 37503747
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.
    Diabetes Obes Metab; 2019 Aug 01; 21(8):1925-1934. PubMed ID: 31050099
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
    Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G.
    Am J Manag Care; 2019 May 01; 25(5):231-238. PubMed ID: 31120717
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.
    Heyward J, Christopher J, Sarkar S, Shin JI, Kalyani RR, Alexander GC.
    Diabetes Obes Metab; 2021 Aug 01; 23(8):1843-1850. PubMed ID: 33881795
    [Abstract] [Full Text] [Related]

  • 19. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
    Alkabbani W, Shah BR, Zongo A, Eurich DT, Alsabbagh MW, Gamble JM.
    Diabetes Obes Metab; 2023 Dec 01; 25(12):3490-3500. PubMed ID: 37563767
    [Abstract] [Full Text] [Related]

  • 20. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM.
    Postgrad Med; 2015 Jun 01; 127(5):463-79. PubMed ID: 25956345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.